d Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed or refractory (r/r) large B-cell lymphomas that have received 2 or more systemic therapies (LBCL) Adult patients, including diffuse large B-cell lymphoma (DLBCL), DLBCL originating from low-grade lymphoma and high-grade cell lymphoma.
Zynlonta is an antibody-conjugated drug (ADC) that targets CD19 and has been granted accelerated approval through a priority review process.
It is worth mentioning that Zynlonta is the first and only CD19-targeted ADC as a single agent to treat adult patients with r/r DLBCL. The approval of the drug for marketing will address the unmet medical needs of a wide range of third-line and multi-line (3L+) r/r DLBCL patients, including DLBCL not otherwise specified, low-grade lymphoma and high-grade B-cell lymphoma Of DLBCL patients.
PRINCIPAL DISPLAY PANEL-10MG VIAL CARTON
NDC 79952-110-01
Zynlonta™(loncastuximab tesirine-lpyl)
For Injection
10mg/vial
For Intravenous Infusion Only
Reconstitute and dilute
prior to administration
One Single-Dose Vial
Discard unused portion
CAUTION: Hazardous Agent
Rx Only
ADC™
THERAPEUTICS |
